Search research articles
Contact Us
Filters
Showing results (111-120 of 162) with videos related to
Page
of 17
Sort By:
Leukemia & Lymphoma
|
July 15, 2021
Cereblon pathway biomarkers and immune profiles in patients with myeloma receiving post-ASCT lenalidomide maintenance (LEOPARD)
Anna Kalff, Tiffany Khong, Malarmathy Ramachandran, et al.
Cancer Discovery
|
December 18, 2020
A Critical Role for Fas-Mediated Off-Target Tumor Killing in T-cell Immunotherapy
Ranjan Upadhyay, Jonathan A Boiarsky, Gvantsa Pantsulaia, et al.
JCO Precision Oncology
|
June 15, 2022
A Three-Gene Signature Predicts Response to Selinexor in Multiple Myeloma
Paula Restrepo, Sherry Bhalla, Yogita Ghodke-Puranik, et al.
Nature Medicine
|
December 11, 2021
Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy
Oliver Van Oekelen, Adolfo Aleman, Bhaskar Upadhyaya, et al.
Cancer
|
March 18, 2021
Phase 1b trial of isatuximab, an anti-CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma
Thomas G Martin, Nina Shah, Joshua Richter, et al.
Cancer Cell
|
April 7, 2022
Augmentation of humoral and cellular immune responses after third-dose SARS-CoV-2 vaccination and viral neutralization in myeloma patients
Adolfo Aleman, Oliver Van Oekelen, Bhaskar Upadhyaya, et al.
American Journal of Hematology
|
December 10, 2019
Recapturing disease response: A phase 2 study of carfilzomib 56 mg/m<sup>2</sup> in patients with relapsed or refractory multiple myeloma who have progressed on carfilzomib 27 mg/m<sup>2</sup>
Kevin Barley, Larysa Sanchez, Hearn J Cho, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 13, 2025
Clonal hematopoiesis and inflammation predict hematologic toxicity and secondary myeloid malignancies after BCMA-directed chimeric antigen receptor T cell therapy
Zachary M Avigan, Jerrel Catlett, Saoirse Bodnar, et al.
Cancer Cell
|
October 27, 2021
Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma
Adolfo Aleman, Bhaskar Upadhyaya, Kevin Tuballes, et al.
Oncotarget
|
September 12, 2022
Combined epigenetic and immunotherapy for blastic and classical mantle cell lymphoma
Francis R LeBlanc, Zainul S Hasanali, August Stuart, et al.
Page
of 17
Search research articles
Search
Showing results (111-120 of 162) with videos related to
Sort By:
Page
of 17
Leukemia & Lymphoma
|
July 15, 2021
Cereblon pathway biomarkers and immune profiles in patients with myeloma receiving post-ASCT lenalidomide maintenance (LEOPARD)
Anna Kalff, Tiffany Khong, Malarmathy Ramachandran, et al.
Cancer Discovery
|
December 18, 2020
A Critical Role for Fas-Mediated Off-Target Tumor Killing in T-cell Immunotherapy
Ranjan Upadhyay, Jonathan A Boiarsky, Gvantsa Pantsulaia, et al.
JCO Precision Oncology
|
June 15, 2022
A Three-Gene Signature Predicts Response to Selinexor in Multiple Myeloma
Paula Restrepo, Sherry Bhalla, Yogita Ghodke-Puranik, et al.
Nature Medicine
|
December 11, 2021
Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy
Oliver Van Oekelen, Adolfo Aleman, Bhaskar Upadhyaya, et al.
Cancer
|
March 18, 2021
Phase 1b trial of isatuximab, an anti-CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma
Thomas G Martin, Nina Shah, Joshua Richter, et al.
Cancer Cell
|
April 7, 2022
Augmentation of humoral and cellular immune responses after third-dose SARS-CoV-2 vaccination and viral neutralization in myeloma patients
Adolfo Aleman, Oliver Van Oekelen, Bhaskar Upadhyaya, et al.
American Journal of Hematology
|
December 10, 2019
Recapturing disease response: A phase 2 study of carfilzomib 56 mg/m<sup>2</sup> in patients with relapsed or refractory multiple myeloma who have progressed on carfilzomib 27 mg/m<sup>2</sup>
Kevin Barley, Larysa Sanchez, Hearn J Cho, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 13, 2025
Clonal hematopoiesis and inflammation predict hematologic toxicity and secondary myeloid malignancies after BCMA-directed chimeric antigen receptor T cell therapy
Zachary M Avigan, Jerrel Catlett, Saoirse Bodnar, et al.
Cancer Cell
|
October 27, 2021
Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma
Adolfo Aleman, Bhaskar Upadhyaya, Kevin Tuballes, et al.
Oncotarget
|
September 12, 2022
Combined epigenetic and immunotherapy for blastic and classical mantle cell lymphoma
Francis R LeBlanc, Zainul S Hasanali, August Stuart, et al.
Page
of 17